Utilization of EGFR , ALK, and BRAF Inhibitors in the Treatment of Lung Cancer in Germany
Cancer Reports · 2024
DOI: 10.1002/cnr2.70060 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, 2024. Verfasst von Nikolaj Rischke und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany. Hauptthemen laut MEDLINE: Lung Neoplasms, Anaplastic Lymphoma Kinase, ErbB Receptors, Proto-Oncogene Proteins B-raf. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
There is a lack of real‐world data on the use of targeted cancer drugs requiring molecular tumor diagnostics in the treatment of lung cancer in Germany.
Aims
We aimed to characterize the use of such drugs in lung cancer patients based on longitudinal analyses. Methods and Results Using the GePaRD database (claims data from ~20% of the German population) we identified lung cancer patients diagnosed in 2016 based on a previously developed algorithm and followed them until death, end of continuous insurance, or end of 2019. We determined the proportion of patients treated with at least one of the drugs under study (EGFR, ALK, and BRAF inhibitors). We described these patients regarding demographic characteristics, treatment patterns, and overall survival. We included 7833 incident lung cancer patients. Of these, 392 (5%) were treated with one of the drugs under study, the majority (62%) being female. In 314 out of the 392 patients (80%), the first dispensation was an EGFR inhibitor (afatinib: 54%, erlotinib: 33%), and in 72 patients (18%), it was an ALK inhibitor (crizotinib: 90%). The proportion of patients treated with these drugs was 4.8% in West Germany and 6.2% in East Germany. About half of these patients had chemotherapy before targeted therapy. Median overall survival after the first targeted therapy was 22 months.
Conclusion
One twentieth of lung cancer patients diagnosed in 2016 in Germany received at least one EGFR, ALK, or BRAF inhibitor during follow‐up. The proportion was higher in East than in West Germany. As the development and availability of new cancer drugs is a dynamic area, regularly updated utilization studies—ideally as cross‐country‐comparisons—are required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.
- Faculty of Human and Health Sciences, University of Bremen, Bremen, Germany.
ORCID-Profile: Nikolaj Rischke
Zitieren
APA
Rischke, N., Kanbach, J., & Haug, U. (2024). Utilization of EGFR , ALK, and BRAF Inhibitors in the Treatment of Lung Cancer in Germany. Cancer Reports. https://doi.org/10.1002/cnr2.70060
Vancouver
Rischke N, Kanbach J, Haug U. Utilization of EGFR , ALK, and BRAF Inhibitors in the Treatment of Lung Cancer in Germany. Cancer Reports. 2024. doi:10.1002/cnr2.70060
BibTeX
@article{Rischke2024,
author = {Rischke, Nikolaj and Kanbach, Josephine and Haug, Ulrike},
title = {Utilization of EGFR , ALK, and BRAF Inhibitors in the Treatment of Lung Cancer in Germany},
journal = {Cancer Reports},
year = {2024},
doi = {10.1002/cnr2.70060}
}
EUVIMED